Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME Study

American Journal of Respiratory and Critical Care Medicine

Volumn 197, Issue 9, 2018, Pages 1223-1226

  Papi, Alberto ^a   Kostikas, Konstantinos ^b   Wedzicha, Jadwiga A ^c   Vogelmeier, Claus F ^d   Roche, Nicolas ^e   Shen, Steven ^b   Banerji, Donald ^b   Fogel, Robert ^b   Patalano, Francesco ^b   Chapman, Kenneth R ^f,g  

^a UNIVERSITY OF FERRARA   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; HOSPITALIZATION; HUMAN; LETTER; PRIORITY JOURNAL; ADULT; AGED; BLOOD; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85041240104     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201709-1822LE     Document Type: Letter

References (8)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2017 [accessed 2017 May 26]. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosismanagement- prevention-copd/.
2. Calverley PM, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EF, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:1219–1221.
3. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523–525.
4. Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2017;12:907–922.
5. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al.; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374: 2222–2234.
6. Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial. Am J Respir Crit Care Med 2017;195:1189–1197.
7. Oshagbemi OA, Burden AM, Braeken DCW, Henskens Y, Wouters EFM, Driessen JHM, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med 2017;195:1402–1404.
8. Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis 2017;12:1819–1824.